SCHEMBL970044

SCHEMBL970044

Fc1cccc(-c2ccccn2)c1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.50
LMNA P02545 3/20 0.50
CCR1 P32246 2/20 0.50
CCR5 P51681 2/20 0.50
CCR8 P51685 2/20 0.50
CYP1A2 P05177 1/20 0.50
POLB P06746 1/20 0.50
METAP1 P53582 1/20 0.50
BLM P54132 1/20 0.50
HIF1A Q16665 1/20 0.50
DOHH Q9BU89 1/20 0.50
P4HTM Q9NXG6 1/20 0.50
HTT P42858 4/20 0.48
L3MBTL1 Q9Y468 4/20 0.48
TP53 P04637 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
TDP1 Q9NUW8 3/20 0.48
ALOX15 P16050 2/20 0.48
ALPL P05186 1/20 0.48
HSP90AA1 P07900 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30888806 1.00 KDM4E (0.50) KDM4ELMNACCR1CCR5CCR8
SCHEMBL30022590 0.98 KDM4E (0.48) KDM4ELMNACCR1CCR5CCR8
SCHEMBL29986122 0.98 KDM4E (0.48) KDM4ELMNACCR1CCR5CCR8
SCHEMBL1780998 0.85 KDM4E (0.56) KDM4ELMNACCR1CCR5CCR8
SCHEMBL7879319 0.85 KDM4E (0.49) KDM4ELMNACCR1CCR5CCR8
SCHEMBL29914907 0.85 KDM4E (0.46) KDM4ELMNACCR1CCR5CCR8
SCHEMBL1356335 0.84 KDM4E (0.50) KDM4ELMNACCR1CCR5CCR8
SCHEMBL29901541 0.84 KDM4E (0.50) KDM4ELMNACCR1CCR5CCR8
2-Picolinic Acid SCHEMBL5670387 0.83 LMNA (0.56) KDM4ELMNAP4HTML3MBTL1NPC1
SCHEMBL3774471 0.81 TGFBR1 (0.45) KDM4ELMNACCR1CCR5CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118619998-A Ir (C ' ≡ ') (C ' ≡N ') (C ' ++C ') ') configuration-based blue light tri-heteroleptic iridium (III) complex and preparation method thereof 西北大学 2024-09-10 CN claimed
CN-118344407-A Ir (C ' ≡ ') (C ' ≡N ') (N ' +O) -configuration-based blue light asymmetric tri-heteroleptic iridium (III) complex and preparation and application thereof 西北大学 2024-07-16 CN claimed
EP-2350106-B1 PHOSPHORESCENT IRIDIUM COMPLEXES BOE TECHNOLOGY GROUP CO LTD (CN) 2018-05-09 EP claimed
CN-102203109-B Phosphorescent iridium complexes GEN ELECTRIC 2014-08-20 CN claimed
CN-101931054-B White organic light emitting device IND TECH RES INST 2012-05-30 CN claimed
CN-102203109-A Phosphorescent iridium complexes GEN ELECTRIC 2011-09-28 CN claimed
EP-2350106-A1 PHOSPHORESCENT IRIDIUM COMPLEXES General Electric Company (US) 2011-08-03 EP claimed
US-7740956-B2 Organic electroluminescent device FUJIFILM CORPORATION (JP) 2010-06-22 US claimed
WO-2010051100-A1 PHOSPHORESCENT IRIDIUM COMPLEXES GENERAL ELECTRIC COMPANY (US) 2010-05-06 WO claimed
US-20100105852-A1 PHOSPHORESCENT IRIDIUM COMPLEXES GENERAL ELECTRIC COMPANY (US) 2010-04-29 US claimed
EP-1086194-B1 MONOSTABLE FERROELECTRIC ACTIVE MATRIX DISPLAY AVENTIS RES & TECH GMBH & CO (DE) 2003-05-21 EP claimed
US-6551668-B1 Monodomain liquid crystal layer with an unambiguously defined direction of the layer normal z of the smectite phase wherein the layer normal z and the preferential direction n of the nematic or cholesteric phase (N* phase) form an angle of >/= 5 AVENTIS RESEARCH & TECHNOLOGIES (DE) 2003-04-22 US claimed
CN-118619998-A Ir (C ' ≡ ') (C ' ≡N ') (C ' ++C ') ') configuration-based blue light tri-heteroleptic iridium (III) complex and preparation method thereof 西北大学 2024-09-10 CN disclosed
CN-118344407-A Ir (C ' ≡ ') (C ' ≡N ') (N ' +O) -configuration-based blue light asymmetric tri-heteroleptic iridium (III) complex and preparation and application thereof 西北大学 2024-07-16 CN disclosed
CN-117940414-A Compounds for targeting IRAK4 protein degradation 渤健马萨诸塞州股份有限公司 2024-04-26 CN disclosed
CN-117447492-A Polypyridine ligand for magnesium ion detection, iridium complex probe and preparation thereof 南京邮电大学 2024-01-26 CN disclosed
CN-1397559-A Luminous organic intermetallic compound and luminous element SANYO ELECTRIC CO (JP) 2003-02-19 CN disclosed
US-6413448-B1 ESTERS; DOPANTS; LONGER CHIRAL SMECTIC PHASE PITCH; HIGHER TILT ANGLE; LOWER VISCOSITY; CRYSTALLIZATION SUPPRESSION; IMPROVED SOLUBILITY; BROADER C* PHASE TEMPERATURE RANGE DISPLAYTECH, INC. 2002-07-02 US disclosed
WO-2000065801-A9 CYCLOHEXYL- AND CYCLOHEXENYL-SUBSTITUTED LIQUID CRYSTALS WITH LOW BIREFRINGENCE DISPLAYTECH INC (US) 2001-04-12 WO disclosed
WO-2000065801-A1 CYCLOHEXYL- AND CYCLOHEXENYL-SUBSTITUTED LIQUID CRYSTALS WITH LOW BIREFRINGENCE DISPLAYTECH, INC. (US) 2000-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105852-A1 PHOSPHORESCENT IRIDIUM COMPLEXES IGF1R, IRS1, IGF2R KDM4E 4381/4885LMNA 4431/4885CCR1 427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.